Latest California Healthline Stories
A Spoonful Of Kids’ Medicine Makes The Profits Go Up
Even as drug pricing issues continue to draw scrutiny, federal safety regulations and incentives offer drug companies a new avenue to get a sweet return on their development costs.
Drugmakers Dramatically Boosted Lobbying Spending In Trump’s First Quarter
With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
With Drug Costs In Crosshairs, Health Firms Gave Generously To Trump’s Inauguration
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
Readers: Training Patients To Advocate For Their Illnesses Is ‘A Virtue Not A Sin’
Readers react to and comment on recent stories.
Nonprofit Linked To PhRMA Rolls Out Campaign To Block Drug Imports
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
Kids With Hepatitis C Get New Drugs And Coverage May Prove Easier Than For Adults
The drugs, approved by the FDA for children earlier this month, can run $100,000 for a course of treatment.
Drugmakers Help Turn Patients With Rare Diseases Into D.C. Lobbyists
Amplifying the “patient voice,” those with the rarest afflictions are trained to become powerful advocates for new drugs and legislation that would help the industry.
Another Circle Of Hell: Surviving Opioids In The Fentanyl Era
Unlike heroin, fentanyl routinely shuts down breathing in seconds, and it’s becoming more common.
Trump’s Promise To Rein In Drug Prices Could Open Floodgate To Importation Laws
Sen. Bernie Sanders’ bill to allow Americans to buy cheaper medicines from Canada would bypass a requirement that blocked past legislative efforts over two decades.
GAO To Launch Investigation Of FDA’s Orphan Drug Program
The Government Accountability Office said it will investigate potential abuses of the orphan drug program, which offers incentives to drugmakers to develop medicines for rare diseases.